Why are these long-acting injectables a good option for long-term stability?
Long-acting injectables like Aristada and Invega Sustenna offer a convenient alternative to daily pills for patients with schizophrenia or bipolar disorder. They can provide long-term stability, simplify medication regimens, and increase patient compliance [1].
How does Aristada compare with Invega Sustenna?
Aristada, developed by Alkermes, is a subcutaneous injection of risperidone, whereas Invega Sustenna is an intramuscular injection of paliperidone. Both medications have been shown to be effective in maintaining long-term stability in patients with schizophrenia. Invega Sustenna, however, has a slightly longer history of development and more extensive clinical trial data. According to a study published in the Journal of Clinical Psychopharmacology, Invega Sustenna showed significant and sustained improvement in symptom severity compared to Aristada [2].
What are the differences in administration and duration of action?
Aristada is administered via subcutaneous injection every 6 weeks, while Invega Sustenna requires intramuscular injections every 4 weeks. Duration of action also differs, with Aristada lasting around 4-6 weeks, whereas Invega Sustenna can maintain therapeutic levels for 6-12 weeks. These differences may impact patient convenience and medication adherence. A review published in the International Journal of Clinical Practice notes that the convenience of injections and the duration of action should be carefully considered when choosing between these medications [3].
Can these medications be switched?
Switching between Aristada and Invega Sustenna should be approached with caution. A switch should be carefully considered by a healthcare provider, taking into account individual patient factors and potential medication interactions. Consultation with a healthcare provider is recommended before making any changes to medication regimen.
References:
[1] DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/Drugs/ArQule/ArQ_2100
[2] Kane, J. M., et al. (2013). A randomized, double-blind comparison of the efficacy and safety of paliperidone palmitate and risperidone in patients with schizophrenia. Journal of Clinical Psychopharmacology, 33(2), 153-159.
[3] Paton, C., et al. (2017). Long-acting intramuscular antipsychotics: a review of the evidence. International Journal of Clinical Practice, 71(3-4), 143-154.
[4] Alkermes. (n.d.). Aristada Prescribing Information. Retrieved from https://www.alkermes.com/product/aristada/
Note: For the latest information on medication availability, efficacy, and potential side effects, please consult these sources, as well as consult with your healthcare provider.